Rheuma Tv

Leptin, an adipokine secreted by fat tissue, plays a dual role in regulating energy balance and modulating immune function. Now, a recent study published in Medicine (Baltimore) revealed that obesity-related dysregulation in circulating adipokines might play a potential role in the pathogenesis of systemic lupus erythematosus (SLE). The cross-sectional study examined the association between serum … Read more

Growing evidence suggests that the neutrophil-to-lymphocyte ratio (NLR) could complement traditional biomarkers in rheumatoid arthritis (RA) management by aiding early diagnosis, monitoring treatment response, and potentially predicting disease flares—particularly in resource-limited settings. Now, a recent study published in Medicine (Baltimore) further supports this potential, demonstrating that NLR is an independent predictor of RA diagnosis and … Read more

Sleep disturbance is a core feature of fibromyalgia, often presenting as nonrestorative sleep in which patients wake feeling unrefreshed despite adequate hours in bed. This poor quality sleep lowers pain thresholds, amplifies central sensitization, and exacerbates the widespread musculoskeletal pain that defines the disorder. A new study published in Medicine (Baltimore) now sheds light on … Read more

A recent study published in The Lancet Rheumatology demonstrated that sarilumab led to clinically meaningful improvements in health-related quality of life, supporting its use in patients with polymyalgia rheumatica inadequately managed with glucocorticoid monotherapy.  This phase 3, double-blind, randomised controlled trial was conducted across 60 centres in 17 countries and enrolled 118 patients aged 50 … Read more

A multicenter, open-label clinical trial published in Medicine (Baltimore) has found that a low-dose combination of rosuvastatin and ezetimibe is both effective and safe in lowering low-density lipoprotein cholesterol (LDL-C) levels in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). The only independent predictor of treatment response was the baseline LDL-C level.  The study enrolled … Read more

A recent study published in Clinical Rheumatology demonstrated that NLRC4 inflammasome activation may contribute to ankylosing spondylitis (AS) pathogenesis by targeting caspase-1 and regulating monocyte pyroptosis. The investigation included peripheral blood samples from 50 AS patients and 50 matched controls, with mRNA expression levels of NLRC4, CASP1, and GSDMD-N quantified in peripheral blood mononuclear cells, … Read more

A Phase 1b clinical trial published in BMC Pharmacology and Toxicology demonstrated that QX002N, an investigational anti–interleukin-17A (IL-17A) monoclonal antibody, exhibited favorable safety and promising efficacy signals in Chinese patients with active ankylosing spondylitis (AS). The randomized, double-blind, placebo-controlled study evaluated multiple ascending doses of the subcutaneous treatment over a 14-week follow-up period.  Safety analysis … Read more

In the 48-week, phase II PAISLEY trial published in Lupus Science & Medicine, deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, showed meaningful improvements in patient-reported outcomes among individuals with active systemic lupus erythematosus (SLE). The study enrolled 363 patients who were randomised to receive a placebo or varying doses of deucravacitinib.   By week 48, patients … Read more